Peroxisome proliferator-activated receptor-γ agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution

Qiang Yao, Krzysztof Pawlaczyk, Ernesto Rodríguez Ayala, Malgorzata Kuzlan, Arkadiusz Styszynski, Andrzej Breborowicz, Olof Heimbürger, Jiaqi Qian, Peter Stenvinkel, Jonas Axelsson, Bengt Lindholm

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: To evaluate if peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists have a potential protective effect on the peritoneum changes induced by bioincompatible peritoneal dialysis (PD) solution in vivo. Methods: Male Wistar rats were dialyzed three times daily for 28 days with 1.36% Dianeal® (two groups: with (D+R) or without (D) rosiglitazone) or 1.36% Physioneal® (two groups: with (P+R) or without (P) rosiglitazone). Peritoneal transport of fluid and small solutes was assessed. Nine rats that did not receive dialysis served as controls. Results: Significant morphological changes were found in the D group compared with controls. Additional use of rosiglitazone in the D+R group resulted in less morphological changes and expression of collagen I as well as an increased drainage volume. The expression of VEGF was inhibited by rosiglitazone while no apparent effect was found regarding TGF/Smad pathway. Conclusions: The addition of rosiglitazone to standard dialysis fluids can maintain the peritoneal morphology and increase ultrafiltration in a PD rat model.

Original languageEnglish (US)
Pages (from-to)575-582
Number of pages8
JournalBlood Purification
Volume24
Issue number5-6
DOIs
StatePublished - Dec 2006
Externally publishedYes

Fingerprint

rosiglitazone
Peroxisome Proliferator-Activated Receptors
Dialysis Solutions
Peritoneal Dialysis
Dialysis
Ascitic Fluid
Peritoneum
Ultrafiltration
Vascular Endothelial Growth Factor A
Wistar Rats
Drainage
Collagen

Keywords

  • Biocompatible solution
  • Fibrosis
  • Peritoneal dialysis
  • Peroxisome proliferator-activated receptor-γ agonist

ASJC Scopus subject areas

  • Nephrology
  • Hematology

Cite this

Peroxisome proliferator-activated receptor-γ agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution. / Yao, Qiang; Pawlaczyk, Krzysztof; Ayala, Ernesto Rodríguez; Kuzlan, Malgorzata; Styszynski, Arkadiusz; Breborowicz, Andrzej; Heimbürger, Olof; Qian, Jiaqi; Stenvinkel, Peter; Axelsson, Jonas; Lindholm, Bengt.

In: Blood Purification, Vol. 24, No. 5-6, 12.2006, p. 575-582.

Research output: Contribution to journalArticle

Yao, Q, Pawlaczyk, K, Ayala, ER, Kuzlan, M, Styszynski, A, Breborowicz, A, Heimbürger, O, Qian, J, Stenvinkel, P, Axelsson, J & Lindholm, B 2006, 'Peroxisome proliferator-activated receptor-γ agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution', Blood Purification, vol. 24, no. 5-6, pp. 575-582. https://doi.org/10.1159/000097081
Yao, Qiang ; Pawlaczyk, Krzysztof ; Ayala, Ernesto Rodríguez ; Kuzlan, Malgorzata ; Styszynski, Arkadiusz ; Breborowicz, Andrzej ; Heimbürger, Olof ; Qian, Jiaqi ; Stenvinkel, Peter ; Axelsson, Jonas ; Lindholm, Bengt. / Peroxisome proliferator-activated receptor-γ agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution. In: Blood Purification. 2006 ; Vol. 24, No. 5-6. pp. 575-582.
@article{0e908e9bda464183b8d13f4b01fb4cd5,
title = "Peroxisome proliferator-activated receptor-γ agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution",
abstract = "Background: To evaluate if peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists have a potential protective effect on the peritoneum changes induced by bioincompatible peritoneal dialysis (PD) solution in vivo. Methods: Male Wistar rats were dialyzed three times daily for 28 days with 1.36{\%} Dianeal{\circledR} (two groups: with (D+R) or without (D) rosiglitazone) or 1.36{\%} Physioneal{\circledR} (two groups: with (P+R) or without (P) rosiglitazone). Peritoneal transport of fluid and small solutes was assessed. Nine rats that did not receive dialysis served as controls. Results: Significant morphological changes were found in the D group compared with controls. Additional use of rosiglitazone in the D+R group resulted in less morphological changes and expression of collagen I as well as an increased drainage volume. The expression of VEGF was inhibited by rosiglitazone while no apparent effect was found regarding TGF/Smad pathway. Conclusions: The addition of rosiglitazone to standard dialysis fluids can maintain the peritoneal morphology and increase ultrafiltration in a PD rat model.",
keywords = "Biocompatible solution, Fibrosis, Peritoneal dialysis, Peroxisome proliferator-activated receptor-γ agonist",
author = "Qiang Yao and Krzysztof Pawlaczyk and Ayala, {Ernesto Rodr{\'i}guez} and Malgorzata Kuzlan and Arkadiusz Styszynski and Andrzej Breborowicz and Olof Heimb{\"u}rger and Jiaqi Qian and Peter Stenvinkel and Jonas Axelsson and Bengt Lindholm",
year = "2006",
month = "12",
doi = "10.1159/000097081",
language = "English (US)",
volume = "24",
pages = "575--582",
journal = "Blood Purification",
issn = "0253-5068",
publisher = "S. Karger AG",
number = "5-6",

}

TY - JOUR

T1 - Peroxisome proliferator-activated receptor-γ agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution

AU - Yao, Qiang

AU - Pawlaczyk, Krzysztof

AU - Ayala, Ernesto Rodríguez

AU - Kuzlan, Malgorzata

AU - Styszynski, Arkadiusz

AU - Breborowicz, Andrzej

AU - Heimbürger, Olof

AU - Qian, Jiaqi

AU - Stenvinkel, Peter

AU - Axelsson, Jonas

AU - Lindholm, Bengt

PY - 2006/12

Y1 - 2006/12

N2 - Background: To evaluate if peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists have a potential protective effect on the peritoneum changes induced by bioincompatible peritoneal dialysis (PD) solution in vivo. Methods: Male Wistar rats were dialyzed three times daily for 28 days with 1.36% Dianeal® (two groups: with (D+R) or without (D) rosiglitazone) or 1.36% Physioneal® (two groups: with (P+R) or without (P) rosiglitazone). Peritoneal transport of fluid and small solutes was assessed. Nine rats that did not receive dialysis served as controls. Results: Significant morphological changes were found in the D group compared with controls. Additional use of rosiglitazone in the D+R group resulted in less morphological changes and expression of collagen I as well as an increased drainage volume. The expression of VEGF was inhibited by rosiglitazone while no apparent effect was found regarding TGF/Smad pathway. Conclusions: The addition of rosiglitazone to standard dialysis fluids can maintain the peritoneal morphology and increase ultrafiltration in a PD rat model.

AB - Background: To evaluate if peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists have a potential protective effect on the peritoneum changes induced by bioincompatible peritoneal dialysis (PD) solution in vivo. Methods: Male Wistar rats were dialyzed three times daily for 28 days with 1.36% Dianeal® (two groups: with (D+R) or without (D) rosiglitazone) or 1.36% Physioneal® (two groups: with (P+R) or without (P) rosiglitazone). Peritoneal transport of fluid and small solutes was assessed. Nine rats that did not receive dialysis served as controls. Results: Significant morphological changes were found in the D group compared with controls. Additional use of rosiglitazone in the D+R group resulted in less morphological changes and expression of collagen I as well as an increased drainage volume. The expression of VEGF was inhibited by rosiglitazone while no apparent effect was found regarding TGF/Smad pathway. Conclusions: The addition of rosiglitazone to standard dialysis fluids can maintain the peritoneal morphology and increase ultrafiltration in a PD rat model.

KW - Biocompatible solution

KW - Fibrosis

KW - Peritoneal dialysis

KW - Peroxisome proliferator-activated receptor-γ agonist

UR - http://www.scopus.com/inward/record.url?scp=33845947340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845947340&partnerID=8YFLogxK

U2 - 10.1159/000097081

DO - 10.1159/000097081

M3 - Article

C2 - 17124426

AN - SCOPUS:33845947340

VL - 24

SP - 575

EP - 582

JO - Blood Purification

JF - Blood Purification

SN - 0253-5068

IS - 5-6

ER -